Precision BioSciences

Precision BioSciences was honored to join the CureDuchenne FUTURES National Conference in Orlando, participating on the Science Main Stage and in the exhibit hall.

Gary Owens, Senior Director Gene Therapy / Program Lead, at Precision, presented in the Gene Therapy and Gene Editing session, and our team spent time at our booth listening, learning, and connecting with families and clinicians from across the Duchenne community.

Precisioneer Crystal Gordon’s 44‑kilometer birthday run in support of the Jett Foundation is an incredible example of the Duchenne community’s strength and solidarity.

As part of the team at Precision BioSciences, Crystal brings that same commitment to our work on PBGENE‑DMD and the FUNCTION‑DMD Phase 1/2 clinical study for individuals living with Duchenne muscular dystrophy.

Precision is proud to support employees who go above and beyond, both in the lab and in their personal lives, to help move science forward and shine a brighter light on families impacted by Duchenne.

https://loom.ly/MKDV6xI

Precision BioSciences announced a late‑breaking poster presentation for PBGENE‑HBV at the European Association for the Study of the Liver (EASL) Congress 2026!

Precision will present new clinical biopsy findings from the ongoing Phase 1 ELIMINATE‑B trial evaluating PBGENE‑HBV, a first‑in‑class in vivo gene editing treatment candidate designed to eliminate cccDNA and inactivate integrated hepatitis B virus (HBV) DNA in adults with chronic hepatitis B.

Read the full release, https://loom.ly/gNTvRlQ

Nothing beats learning side‑by‑side with families.

The Precision BioSciences team recently joined Jett Foundation’s Family Workshop in Salt Lake City, Utah, to listen, learn, and speak with families impacted by Duchenne muscular dystrophy.

We appreciated the opportunity to share more about PBGENE‑DMD and to hear directly from caregivers and clinicians about what matters most as new treatment options move forward.

Learn more about PBGENE-DMD and the Phase 1/2 FUNCTION-DMD study here, https://loom.ly/-wqqxIk

Precision BioSciences is expanding its global Phase 1 ELIMINATE‑B trial evaluating PBGENE‑HBV following clinical trial application approval in two European countries.

“Expanding ELIMINATE-B into hepatitis sites in France and Romania is an important step in the continued development of PBGENE-HBV, the only gene editing therapy uniquely designed to eliminate cccDNA,” said Cindy Atwell, Chief Development and Business Officer of Precision BioSciences. “Given the strong investigator interest in PBGENE-HBV, especially following the late breaker oral presentation at The Liver Conference 2025, these new trial sites will build on our existing global clinical trial footprint as we advance PBGENE-HBV through the ELIMINATE-B trial.”

To learn more, visit https://loom.ly/ore3n7A

Precision BioSciences was proud to join the 2026 MDA Clinical & Scientific Conference last month, where the team presented new preclinical data on PBGENE‑DMD, the company’s in vivo gene editing candidate designed to restore near full‑length dystrophin and potentially benefit boys with mutations between exons 45–55.

As Debra Miller of CureDuchenne noted, “IND clearance for PBGENE‑DMD is an exciting step forward, and we look forward to collaborating to help connect innovation with the patient families we serve.”

Read the full release, https://loom.ly/-wqqxIk

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE‑DMD, an in vivo gene editing candidate for the treatment of Duchenne muscular dystrophy (DMD)!

This designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.

“Fast Track designation is an important regulatory milestone for PBGENE-DMD and reflects the significant unmet need in DMD,” said Michael Amoroso, Chief Executive Officer of Precision BioSciences. “We believe this designation, together with our recent IND clearance, supports PBGENE-DMD’s continued momentum towards clinical investigation in boys living with DMD.”

Read the full PR: https://loom.ly/RX7H4kE